Literature DB >> 17846734

[Current aspects of secondary prevention of ischemic stroke].

R Weber1, H C Diener, M Grond.   

Abstract

Secondary prevention including lifestyle modulation and medical interventions remain the basic principle in our therapeutic challenge to reduce the risk of recurrent subsequent ischemic stroke. The substantial number of randomized clinical trials published in the past 2 years was broadened our evidence-based therapeutic armament in the field of secondary prevention of ischemic stroke. An update of current knowledge in secondary stroke prevention is presented in this review on the basis of the 2007 revised guidelines of the German Neurological Society and the German Stroke Society. Special emphasis is given to medical and nonmedical modulation of cardiovascular risk factors (treatment of hypertension, hypercholesterolemia, and diabetes mellitus), prophylactic vitamin supplementation, and the use of platelet inhibitors and treatment of symptomatic intracranial stenosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17846734     DOI: 10.1007/s00115-007-2351-8

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  39 in total

1.  Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.

Authors:  Nils Wahlgren; Niaz Ahmed; Antoni Dávalos; Gary A Ford; Martin Grond; Werner Hacke; Michael G Hennerici; Markku Kaste; Sonja Kuelkens; Vincent Larrue; Kennedy R Lees; Risto O Roine; Lauri Soinne; Danilo Toni; Geert Vanhooren
Journal:  Lancet       Date:  2007-01-27       Impact factor: 79.321

2.  High-dose atorvastatin after stroke or transient ischemic attack.

Authors:  Pierre Amarenco; Julien Bogousslavsky; Alfred Callahan; Larry B Goldstein; Michael Hennerici; Amy E Rudolph; Henrik Sillesen; Lisa Simunovic; Michael Szarek; K M A Welch; Justin A Zivin
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

3.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

4.  Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin-Aspirin Recurrent Stroke Study.

Authors:  Ralph L Sacco; Shyam Prabhakaran; J L P Thompson; Amy Murphy; Robert R Sciacca; Bruce Levin; J-P Mohr
Journal:  Cerebrovasc Dis       Date:  2006-03-27       Impact factor: 2.762

5.  A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group.

Authors: 
Journal:  Ann Neurol       Date:  1997-12       Impact factor: 10.422

6.  Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

Authors:  André J Scheen; Nick Finer; Priscilla Hollander; Michael D Jensen; Luc F Van Gaal
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

7.  Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.

Authors:  Deepak L Bhatt; Marcus D Flather; Werner Hacke; Peter B Berger; Henry R Black; William E Boden; Patrice Cacoub; Eric A Cohen; Mark A Creager; J Donald Easton; Christian W Hamm; Graeme J Hankey; S Claiborne Johnston; Koon-Hou Mak; Jean-Louis Mas; Gilles Montalescot; Thomas A Pearson; P Gabriel Steg; Steven R Steinhubl; Michael A Weber; Liz Fabry-Ribaudo; Tingfei Hu; Eric J Topol; Keith A A Fox
Journal:  J Am Coll Cardiol       Date:  2007-04-11       Impact factor: 24.094

8.  Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.

Authors:  James F Toole; M René Malinow; Lloyd E Chambless; J David Spence; L Creed Pettigrew; Virginia J Howard; Elizabeth G Sides; Chin-Hua Wang; Meir Stampfer
Journal:  JAMA       Date:  2004-02-04       Impact factor: 56.272

9.  Angioplasty for symptomatic intracranial stenosis: clinical outcome.

Authors:  Michael P Marks; Joan C Wojak; Firas Al-Ali; Mahesh Jayaraman; Mary L Marcellus; John J Connors; Huy M Do
Journal:  Stroke       Date:  2006-02-23       Impact factor: 7.914

Review 10.  Efficacy of folic acid supplementation in stroke prevention: a meta-analysis.

Authors:  Xiaobin Wang; Xianhui Qin; Hakan Demirtas; Jianping Li; Guangyun Mao; Yong Huo; Ningling Sun; Lisheng Liu; Xiping Xu
Journal:  Lancet       Date:  2007-06-02       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.